Status:
UNKNOWN
Antecubital Versus Femoral Approach for Adrenal Venous Sampling
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions:
Hyperaldosteronism
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Subtype diagnosis is crucial for the treatment of primary aldosteronism (PA), which conducts the appropriate treatment strategy. Currently, adrenal venous sampling (AVS) serves as the gold standard fo...
Detailed Description
Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, and its most common subtypes are aldosterone-producing adenoma and idiopathic hyperaldosteronism, which account f...
Eligibility Criteria
Inclusion
- Aged from 18 to 60 with no limits in sex;
- Patients with confirmed primary aldosteronism;
- Patients or their legal representatives sign written informed consent approved by the ethics committee
Exclusion
- Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；
- An estimated glomerular filtration rate \<45 ml/min/1.73 m2, or serum creatinine \>176 μmol/L；
- Patients who refuse adrenalectomy;
- suspected of having an adrenocortical carcinoma;
- allergy to contrast agent;
- pregnant, nursing, or planning to become pregnant
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2023
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT06029803
Start Date
April 1 2022
End Date
November 30 2023
Last Update
September 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100037